Literature DB >> 28271281

The role of radiation in treating glioblastoma: here to stay.

Christopher D Corso1, Ranjit S Bindra1, Minesh P Mehta2.   

Abstract

Despite numerous efforts over the past several decades, few therapeutic breakthroughs in the treatment of GBM have been realized, and even these have yielded only incrementally modest gains. Radiotherapy remains a crucial component in the management of this disease. In this review, the historical basis for inclusion of radiotherapy as part of the therapeutic regimen for GBM is examined. Additionally, an overview of the evidence supporting the modern role of radiotherapy is provided along with a discussion of standard and emerging combined modality therapies. Finally, GBM management guidelines from three professional societies are reviewed.

Entities:  

Keywords:  GBM; History; Radiation

Mesh:

Year:  2017        PMID: 28271281     DOI: 10.1007/s11060-016-2348-x

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  44 in total

1.  The Charing Cross Hospital experience with temozolomide in patients with gliomas.

Authors:  E S Newlands; S M O'Reilly; M G Glaser; M Bower; H Evans; C Brock; M H Brampton; I Colquhoun; P Lewis; J M Rice-Edwards; R D Illingworth; P G Richards
Journal:  Eur J Cancer       Date:  1996-12       Impact factor: 9.162

2.  Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.

Authors:  Annika Malmström; Bjørn Henning Grønberg; Christine Marosi; Roger Stupp; Didier Frappaz; Henrik Schultz; Ufuk Abacioglu; Björn Tavelin; Benoit Lhermitte; Monika E Hegi; Johan Rosell; Roger Henriksson
Journal:  Lancet Oncol       Date:  2012-08-08       Impact factor: 41.316

Review 3.  DNA damage response and growth factor signaling pathways in gliomagenesis and therapeutic resistance.

Authors:  Massimo Squatrito; Eric C Holland
Journal:  Cancer Res       Date:  2011-09-13       Impact factor: 12.701

4.  Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.

Authors:  Stephan A Grupp; Michael Kalos; David Barrett; Richard Aplenc; David L Porter; Susan R Rheingold; David T Teachey; Anne Chew; Bernd Hauck; J Fraser Wright; Michael C Milone; Bruce L Levine; Carl H June
Journal:  N Engl J Med       Date:  2013-03-25       Impact factor: 91.245

5.  Randomized comparisons of radiotherapy and CCNU versus radiotherapy, CCNU plus procarbazine for the treatment of malignant gliomas following surgery. A Southwest Oncology Group Report.

Authors:  H J Eyre; J M Quagliana; J R Eltringham; J Frank; R M O'Bryan; B McDonald; S E Rivkin
Journal:  J Neurooncol       Date:  1983       Impact factor: 4.130

6.  Malignant astrocytomas: focal tumor recurrence after focal external beam radiation therapy.

Authors:  B C Liang; A F Thornton; H M Sandler; H S Greenberg
Journal:  J Neurosurg       Date:  1991-10       Impact factor: 5.115

7.  Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial.

Authors:  W Roa; P M A Brasher; G Bauman; M Anthes; E Bruera; A Chan; B Fisher; D Fulton; S Gulavita; C Hao; S Husain; A Murtha; K Petruk; D Stewart; P Tai; R Urtasun; J G Cairncross; P Forsyth
Journal:  J Clin Oncol       Date:  2004-03-29       Impact factor: 44.544

8.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

9.  Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery.

Authors:  M D Walker; S B Green; D P Byar; E Alexander; U Batzdorf; W H Brooks; W E Hunt; C S MacCarty; M S Mahaley; J Mealey; G Owens; J Ransohoff; J T Robertson; W R Shapiro; K R Smith; C B Wilson; T A Strike
Journal:  N Engl J Med       Date:  1980-12-04       Impact factor: 91.245

10.  Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules.

Authors:  A W Tolcher; S L Gerson; L Denis; C Geyer; L A Hammond; A Patnaik; A D Goetz; G Schwartz; T Edwards; L Reyderman; P Statkevich; D L Cutler; E K Rowinsky
Journal:  Br J Cancer       Date:  2003-04-07       Impact factor: 7.640

View more
  10 in total

Review 1.  From imaging to biology of glioblastoma: new clinical oncology perspectives to the problem of local recurrence.

Authors:  A Zygogianni; M Protopapa; A Kougioumtzopoulou; F Simopoulou; S Nikoloudi; V Kouloulias
Journal:  Clin Transl Oncol       Date:  2018-01-15       Impact factor: 3.405

2.  Tumor-associated alterations in white matter connectivity have prognostic significance in MGMT-unmethylated glioblastoma.

Authors:  Nikhil Rammohan; Alexander Ho; Mohit Saxena; Amishi Bajaj; Tim J Kruser; Craig Horbinski; Alexander Korutz; Matthew Tate; Sean Sachdev
Journal:  J Neurooncol       Date:  2022-05-07       Impact factor: 4.130

3.  Temozolomide - Just a Radiosensitizer?

Authors:  Bernd Kaina; Lea Beltzig; Herwig Strik
Journal:  Front Oncol       Date:  2022-06-16       Impact factor: 5.738

4.  Sedoheptulose Kinase SHPK Expression in Glioblastoma: Emerging Role of the Nonoxidative Pentose Phosphate Pathway in Tumor Proliferation.

Authors:  Sara Franceschi; Francesca Lessi; Mariangela Morelli; Michele Menicagli; Francesco Pasqualetti; Paolo Aretini; Chiara Maria Mazzanti
Journal:  Int J Mol Sci       Date:  2022-05-26       Impact factor: 6.208

5.  The small molecule drug CBL0137 increases the level of DNA damage and the efficacy of radiotherapy for glioblastoma.

Authors:  Miranda M Tallman; Abigail A Zalenski; Amanda M Deighen; Morgan S Schrock; Sherry Mortach; Treg M Grubb; Preetham S Kastury; Kristin Huntoon; Matthew K Summers; Monica Venere
Journal:  Cancer Lett       Date:  2020-11-27       Impact factor: 8.679

Review 6.  The neuro-glial coagulonome: the thrombin receptor and coagulation pathways as major players in neurological diseases.

Authors:  Shany G Gofrit; Efrat Shavit-Stein
Journal:  Neural Regen Res       Date:  2019-12       Impact factor: 5.135

7.  Abrogation of Cellular Senescence Induced by Temozolomide in Glioblastoma Cells: Search for Senolytics.

Authors:  Lea Beltzig; Markus Christmann; Bernd Kaina
Journal:  Cells       Date:  2022-08-19       Impact factor: 7.666

Review 8.  Glioblastoma: Pathogenesis and Current Status of Chemotherapy and Other Novel Treatments.

Authors:  Vilashini Rajaratnam; Mohammad Mohiminul Islam; Maixee Yang; Rachel Slaby; Hilda Martinez Ramirez; Shama Parveen Mirza
Journal:  Cancers (Basel)       Date:  2020-04-10       Impact factor: 6.639

Review 9.  Radiotherapy of Glioblastoma 15 Years after the Landmark Stupp's Trial: More Controversies than Standards?

Authors:  Tomas Kazda; Adam Dziacky; Petr Burkon; Petr Pospisil; Marek Slavik; Zdenek Rehak; Radim Jancalek; Pavel Slampa; Ondrej Slaby; Radek Lakomy
Journal:  Radiol Oncol       Date:  2018-06-06       Impact factor: 4.214

Review 10.  Targeting the Sphingolipid System as a Therapeutic Direction for Glioblastoma.

Authors:  Melinda N Tea; Santosh I Poonnoose; Stuart M Pitson
Journal:  Cancers (Basel)       Date:  2020-01-01       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.